Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Rivastigmine
Dr Reddy's Laboratories (UK) Ltd
N06DA03
Rivastigmine
9.5mg/24hour
Transdermal patch
Transdermal
No Controlled Drug Status
Valid as a prescribable product
BNF: 04110000; GTIN: 05036072005556
PACKAGE LEAFLET: INFORMATION FOR THE USER ALZEST 4.6 MG/24 H TRANSDERMAL PATCH ALZEST 9.5 MG/24 H TRANSDERMAL PATCH Rivastigmine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. WHAT ALZEST IS AND WHAT IT IS USED FOR 2. WHAT YOU NEED TO KNOW BEFORE YOU USE ALZEST 3. HOW TO USE ALZEST 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE ALZEST 6. CONTENTS OF THE PACK AND OTHER INFORMATION 1. WHAT ALZEST IS AND WHAT IT IS USED FOR The active substance of Alzest is rivastigmine. Rivastigmine belongs to a class of substances called cholinesterase inhibitors. In patients with Alzheimer’s dementia, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other). Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, rivastigmine allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease. Alzest is used for the treatment of adult patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE ALZEST DO NOT USE ALZEST • if you are allergic to rivastigmine (the active substance in Alzest) or any of the other ingredients of this medicine (listed in section 6) • if you have ever had an allergic reaction to a similar type of Read the complete document
OBJECT 1 ALZEST 9.5MG/24H TRANSDERMAL PATCH Summary of Product Characteristics Updated 07-Jun-2016 | Dr. Reddy's Laboratories (UK) Ltd 1. Name of the medicinal product Alzest 9.5 mg/24 h Transdermal Patch 2. Qualitative and quantitative composition Each transdermal patch releases 9.5 mg of rivastigmine per 24 hours. Each transdermal patch of 9.2 cm 2 contains 13.8 mg of rivastigmine. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Transdermal patch Each transdermal patch is a thin, matrix-type transdermal patch. The outside of the backing layer is tan coloured. Each patch is printed in orange with RIV-TDS 9.5 mg/24 h. 4. Clinical particulars 4.1 Therapeutic indications Symptomatic treatment of mild to moderately severe Alzheimer's dementia. 4.2 Posology and method of administration Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Diagnosis should be made according to current guidelines. Similar to any treatment initiated in patients with dementia, therapy with rivastigmine should only be started if a caregiver is available to regularly administer and monitor the treatment. Posology TRANSDERMAL PATCHES RIVASTIGMINE _IN VIVO _RELEASE RATES PER 24 H Alzest 4.6 mg/24 h 4.6 mg Alzest 9.5 mg/24 h 9.5 mg Rivastigmine 13.3 mg/24 h* 13.3 mg *The 13.3 mg/24 h dose strength cannot be achieved with this product. For conditions where this strength should be used, please refer to other rivastigmine products for which transdermal patches of the 13.3 mg/24 h strength are available. Initial dose Treatment is started with 4.6 mg/24 h. Maintenance dose After a minimum of four weeks of treatment and if well tolerated according to the treating physician, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, the daily recommended effective dose, which should be continued for as long as the patient continues to demonstrate therapeutic benefit. Dose escalation 9.5 mg/24 h is the recommended daily effective dose which should Read the complete document